Finally you hit the nail on the head. I think to bet on Indian market is not a good option.
Focusing on US, Europe, Japan, HK etc, is top priority. It would not be a good idea to tackle a secondary market via offering a low price.
Just a friendly reminder, MSB, even FDA approval were received next month, I'd bet they would be struggling to survive in a long run, due to constantly burning substantial cash. They were meant to make hefty cash flow from Japan market...
PNV, needs to focus on sales, easy to expand 5 times production capacity by 2025 via investing $25m, still has a good chance to succeed, imo.
Good luck all.
All imo.
Add to My Watchlist
What is My Watchlist?
